Effects of Yoga Therapy (YT) on heart rate variability (HRV) of adults with a history of cancer Circulatory System
Conditions
Interventions
Each participant received a 1:1 YT session (i.e., one participant, one Yoga Therapist
intervention phase 1) and 6 weeks of group-based YT (i.e., 2-3 participants, one Yoga Therapist
intervention phase 2), and repeated assessments were conducted before, during, and after the YT program to assess if changes in outcomes occurred.
Sponsors
University of Ottawa
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. =18 years of age 2. Received a diagnosis of cancer (regardless of time since diagnosis); 3. Not undergone conventional cancer treatments (chemotherapy, radiotherapy, surgery) within the past 3 months and had none scheduled for the next 5 months; 4. Not currently on any cardiac medication; 5. Self-reported no YT practice since their cancer diagnosis; 6. Cleared for physical activity as indicated by physical activity readiness questions, and; 7. Willing and able to provide informed consent in English.
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HRV is measured using a Hexoskin Smart Shirt at all 7 assessment periods (1 = 6 weeks prior to the one-on-one yoga therapy (1:1 YT) session, 2 = 3 weeks prior to the 1:1 YT session, 3 = immediately prior to the 1:1 YT session, 4 = immediately following the 1:1 YT session, 5 = prior to the first group-based YT session, 6 = after the last group-based YT session, 7 = 6 week follow-up) and continuously between assessment 3 and 4 (i.e., throughout the 1:1 YT session). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. General state of regulation for different autonomic functions, namely orthostatic-circulatory, rest/activity, and digestive regulation measured using the Trait and State Autonomic Regulation (aR) scales at assessment periods 1, 2, 3, 5, 6, and 7. 2. Fatigue and its influence on global quality of life over a 7-day period measured using Functional Assessment of Cancer Therapy-Fatigue Scale (FACT-F) at assessment periods 1, 2, 3, 5, 6, and 7. 3. Impairment of cognitive abilities and its impact on quality of life during the past 7 days measured using Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-Cog-Version 3) at assessment periods 1, 2, 3, 5, 6, and 7. 4. Depressive symptomatology during the past week measured using The Center for Epidemiologic Studies Depression (CES-D) short-form Scale at assessment periods 1, 2, 3, 5, 6, and 7. 5. Stress was measured using the Perceived Stress Scale (PSS; 10-item version) at assessment periods 1, 2, 3, 5, 6, and 7. 6. Subjective level of anxiety in specific situations and in general situations measured using The State-Trait Anxiety Inventory (STAI) at assessment periods 1, 2, 3, 4, 5, 6, and 7. 7. Health-related QoL (physical, social, emotional and functional well-being) measured using The Functional Assessment of Cancer Therapy General version 4 (FACT-G-Version 4) at assessment periods 1, 2, 3, 5, 6, and 7. 8. Sense of belonging to the group and sense of commonality with in-group members measured using The Group Identification Scale (GIS) at assessment periods 6 and 7. | — |
Countries
Canada
Contacts
Public ContactJennifer Brunet
Outcome results
None listed